Stage-specific prevalence and progression of sarcopenia among aging hemodialysis patients: a multicenter cross-sectional study

老年血液透析患者肌少症的阶段特异性患病率和进展:一项多中心横断面研究

阅读:5

Abstract

OBJECTIVES: To investigate the stage-specific prevalence and progression mechanisms of sarcopenia in aging patients undergoing maintenance hemodialysis (MHD), and to identify modifiable risk and protective factors relevant to early public health interventions. METHODS: This multicenter cross-sectional study enrolled 448 eligible older adults (aged ≧ 60 years) undergoing maintenance hemodialysis (MHD) from three tertiary hospitals in Bengbu, China, between January and April 2025, using convenience sampling. Sarcopenia was classified according to the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Data on demographics, body composition, nutrition, self-efficacy, physical activity, and inflammation were collected. Logistic regression analyses identified factors associated with sarcopenia onset and progression. RESULTS: Sarcopenia prevalence was 54.0%, with 25.0% at the possible stage, 19.6% confirmed, and 9.4% severe. Key protective factors for sarcopenia onset included female sex, higher basal metabolic rate (BMR), higher Body Mass Index (BMI) and greater self-efficacy (SES6). Risk factors included low physical activity, diabetes, longer dialysis vintage, and malnutrition (MQSGA). Progression to confirmed/severe stages was independently associated with reduced BMI, protein mass, and self-efficacy, along with elevated BMR and physical inactivity. These findings highlight the importance of early screening and personalized preventive strategies in aging MHD populations. CONCLUSION: Sarcopenia is highly prevalent among older adults receiving MHD, with distinct stage-specific progression patterns. This study identified key modifiable risk and protective factors related to both the onset and progression of sarcopenia. Early detection of possible sarcopenia and timely interventions targeting nutrition, physical activity, and self-efficacy may delay progression and promote healthy aging in this population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。